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Abstract
Worldwide, cardiovascular incidents are estimated to cause 17.5 million deaths, 80% of 
which are ischemic strokes or acute coronary syndromes. Cardiovascular disease results 
in a significant financial burden for healthcare system—namely, in 2009, it was 9% of the 
gross health service expenditure in the European Union. Therefore, the development of 
the knowledge about atherosclerosis—initially thought to be solely degenerative disor-
der but now considered a multifactorial inflammatory state—is essential. Acute coronary 
syndrome (ACS) is usually a manifestation of severe reduction in coronary blood flow 
caused by atherosclerotic plaque and thrombus. The pathology of the atherosclerotic 
plaque is complex. Essentially, it is disease of the arterial intima that, through subse-
quent stages, results to luminal narrowing. Over the years, various theories regarding the 
genesis growth and vulnerability of atherosclerotic lesions have been promoted, usually 
focusing on endothelial injury, smooth muscle cell proliferation, lipid accumulation, and, 
more recently, inflammatory reactions.
Keywords: atherothrombosis, atherosclerotic plaque, intravascular thrombus, acute 
coronary syndrome, cardiovascular events, ischemic heart disease, vulnerable plaque, 
plaque erosion
1. Introduction
Ischemic heart disease, despite the significant progress of drug therapy as well as coronary 
revascularization techniques, still represents the most common cause of death in developed 
countries [1]. Social significance of the problem is reflected by analyzing the results of the 
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randomized controlled trials (POLSCREEN, EURO-ACTION, POLCARD, DART, GISSI). The 
above-mentioned trials, as well as other carried out so far, including autopsy studies and 
clinical and experimental studies, have shed new light on the pathogenesis of atherosclerosis, 
which for years was believed to be a disease solely degenerative. It is now known that it is a 
condition characterized by systemic low-grade inflammation [2, 3]. This process begins peri-
natally [4]. Lipid disorders that occur in the mother increase the sensitivity of the fetus to the 
risk factors for atherosclerosis. Moreover, the low birth weight correlates positively with an 
instance of the metabolic syndrome in adulthood [5, 6].
Inflammation affects the compliance of the arteries. It is a response of vascular walls to 
agitation and injury of vascular endothelium (response-to-injury hypothesis) [2, 7]. It has been 
shown that endothelial cells are the main component of the vessel wall that is responsible 
for empowerment of the process of atherogenesis. It has also been suggested that they 
participate in various stages of development, destabilization and cause for plaque rupture 
[8]. Under physiological conditions, the cells of proper endothelium produce substances 
that regulate vascular smooth muscle tension, adhesion and aggregation of platelets and 
the migration of monocytes and polymorphonuclear leukocytes. Damage to the vascu-
lar endothelium, also considered for activation of the inflammation, is characterized by a 
reduced bioavailability of endothelial vascular distending substances (mainly nitric oxide 
[NO] and prostacyclin [PGI]), increased permeability of plasma lipoprotein vessel intima 
and changing the properties from anti-adhesive to pro-adhesive [9, 10]. The state of endo-
thelial cells depends, among other things, on vascular endothelial NO formed under the 
influence of l-arginine NO synthase [10]. This is the endothelial substance responsible for 
the anti-atherosclerotic, vascular distention, anti-inflammatory and anti-coagulant activity 
of vascular endothelium [9, 11]. Factors responsible for endothelium dysfunction include 
elevated LDL cholesterol, high homocysteine, hypoxia, diabetes, oxidative stress (due to 
excessive formation of free radicals of oxygen), bacterial and viral infections (Chlamydia 
pneumoniae, Helicobacter pylori, Herpes virus, Cytomegalovirus). These components of 
atherogenesis cause mainly functional but also morphological damage. Moreover, shear 
stress variability in hypertension causes mechanical injury of endothelial cells [9, 12]. 
Increased sensitivity to the damage is shown in the endothelium of the diabetic patients, 
as its cells can be stimulated, under the influence of the increased concentration of glu-
cose and the accumulation of advanced glycation end-products. These substances, acting 
through the receptors for glycation end products, may induce proinflammatory molecule 
expression in endothelial cells [13].
2. Epidemiology and impact of life style on atherothrombosis
Atherothrombosis is a complication of atherosclerosis. The essence of this process con-
sists of closing or narrowing vessel lumen, which is caused by a clot formation following 
exposure of thrombogenic, lipid rich necrotic core, of the ruptured plaque. Depending 
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on the affected vascular bed, it can manifest as a heart attack or unstable coronary artery 
disease, transient ischemic episode or stroke, as intermittent claudication or acute limb 
ischemia [14].
About 80% of deaths from cardiovascular events occur as a result of a stroke or a heart attack. 
Approximately 17.5 million people die every year due to cardiovascular disease, which is 
approximately 31% of general mortality in the world. Atherothrombosis is the main cause 
of mortality due to cardiovascular diseases (CVD). Approximately 75% of the cases of heart 
attack and approximately 90% of strokes associated with carotid arteries atherosclerosis are 
caused by thrombosis [15].
CVD is a big financial burden for healthcare systems. In 2009, CVD-related costs totaled 106 
billion euros, which was approximately 9% of the total expenditure on health care in the 
European Union [16]. There exists global trend towards the increase in the incidence of life-
style diseases and a decrease in cases of premature death as compared to years on disability. 
In the context of lost years of life and life years on disability, ischemic heart disease (IHD) and 
stroke are, respectively, in the first and third place in the world [17]. About 85–90% of strokes 
are of ischemic etiology [18].
In accordance with meta-analysis, based on an analysis of studies involving a total of more 
than 250,000 people, the risk of death due to CVD in the course of lifetime is approximately 
30%, and taken into account the risk of death and all cardiovascular events dating back to it, 
50% for both sexes, in each age group [19]. Among diabetics, most of whom die due to CVD, 
8 of 10 deaths are due to atherothrombosis [20].
According to the findings of the Global Burden of Disease Study from 2010 onwards, adjusted 
for age, the mortality due to CVD has fallen approximately 20% during the last 80 years of 
the twentieth century [21]. The success of the reduction of mortality due to CVD is associated 
with the development of methods of treatment and better organization of healthcare, as well 
as preventive activities, including non-pharmacological interventions. To the above, one can 
also add changes in tobacco legislation, which can lead to a 15% reduction in the risk of hospi-
talization and a 16% reduction in mortality from coronary heart disease and stroke [22]. Not 
less important are the lifestyle changes, including eating habits. It has been demonstrated that 
appropriate physical activity and dietary intervention can contribute to approximately 35% 
reduction in the risk of death already accepted with adjustment of pharmacologic medication 
[23]. Proper diet contributes to the reduction of cardiovascular events (CVE) in patients after 
55 years of age diagnosed with diabetes or a history of CVE irrespective of the use of drugs in 
secondary prevention [24].
In terms of cardiovascular risk reduction, the introduction of statin therapy was the phar-
macological milestone. This has proven effective in reducing CVE and mortality due to 
CVD [25]. What’s more, their use in low-risk populations decreased by approximately 
30% the relative risk in this population. In addition, for patients intolerant of statins or 
for those who despite optimal therapy fail to achieve their therapeutic goal, Ezetimibe or 
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Evolucumab can be currently used, new drugs of proven efficacy and safety of therapy 
[26, 27]. Ezetimibe connects with Niemann-Pick C1-like 1 (NPC1L1) proteins prevent-
ing absorption of cholesterol from the gastrointestinal tract. Used together with simv-
astatin, it significantly reduced the risk of mortality compared to statin monotherapy. 
Evolocumab is a monoclonal antibody interacting with enzyme PCSK9 (proprotein con-
vertase subtilisin kexin type-9) and significantly lowering LDL-cholesterol and total 
cholesterol and reducing CVE rate in combination with a statin as compared to statin 
monotherapy [26, 27].
Very important element of therapy is patient’s compliance. Adherence of the patient affects the 
effectiveness of the therapy. The review of approximately 20 studies involving a total of over 
375,000 patients showed only 42–61% of adherence to treatment in patients receiving cardio-
vascular drugs as primary prevention and 62–76% adherence in secondary prevention [28].
There are some differences in CVD mortality among different races. Black people have a 
higher risk of death from coronary heart disease and 2–4 times higher risk of ischemic stroke 
than white people. The Asian race and the people of the Pacific Islands are at the highest risk 
for hemorrhagic stroke [29].
Appropriate prevention would reduce the CVD cases by 80% [19, 30]. Unfortunately, there 
are still inequalities between countries. About 80% of deaths from CVD take place in countries 
with low-to-moderate prosperity, in which the frequency of multiple risk factors, especially 
obesity and diabetes mellitus (DM), tends to increase significantly [16]. Interestingly, despite 
the general decline in the consumption of tobacco products, there currently exists three times 
higher risk for smoking in women because of the trend to start the habit at a younger age.
Among patients with CAD, the most common manifestations of atherothrombosis are myo-
cardial infarctions with ST segment elevation (STEMI) and non-ST segment elevation myo-
cardial infarction (NSTEMI). In-hospital mortality in STEMI varies, according to a variety 
of records, around 6–14%. Despite the development of pharmacotherapy and the invasive 
therapy, the mortality rate in 6 months after STEMI is still approximately 12%. Over the last 
decade, the proportion of STEMI has been reduced as compared to NSTEMI. Although, in the 
early years, the population of patients with NSTEMI acute coronary syndrome is character-
ized by lower mortality; after about 2 years, it is similar as in patients with STEMI [31].
3. The role of inflammation in the process of the formation of 
atherosclerosis
Atherosclerosis is a chronic inflammatory disease [9, 32–34]. Due to the damage to the vas-
cular endothelium and the development of inflammatory lesions in the vessel wall, there is 
a tendency to create blood clots leading to the occurrence of the thromboembolism evolving 
from atherosclerotic plaques or closing of the artery lumen at the site of inflamed plaque 
rupture, i.e. thrombotic vessel occlusion. Acute coronary syndromes (ACS) are in the form 
of unstable coronary artery disease (unstable angina—UA) and acute myocardial infarction 
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(AMI)—which includes STEMI and NSTEMI or sudden cardiac death (SCD). Atherosclerosis 
in carotid arteries can lead to transient ischemic attacks (TIA) or ischemic stroke. The cause 
for these complexes, known as cardiovascular syndromes, is a blood thrombosis, forming on 
the surface of the damaged endothelium, a narrowed coronary artery or carotid artery, most 
frequently internal carotid artery (ICA) [9, 32].
Pathophysiological studies have shown that the most common cause of formation of a blood 
clot is rupture of the fibrous cap, which separates the contents of the plaque from the blood 
[9, 13, 33, 35]. This was confirmed in intravascular ultrasound (IVUS) with virtual histology 
(VH-IVUS), optical coherence tomography (OCT) and magnetic resonance imaging (MRI) 
[36, 37]. This mechanism applies to approximately 55–60% (in some studies dating back to 
the 80%) cases of ACS [33, 35, 36]. Other mechanisms are damage of endothelial cells known 
as erosion on the surface of atherosclerotic plaque (plaque erosion) consisting of 30–35% of 
the ACS and of approximately 2–7% endovascular calcifications (calcified nodules) [33, 35]. 
Inflammatory changes ongoing in the atherosclerotic plaque cause a loss of stability making 
it vulnerable to rupture, the so-called unstable atherosclerotic plaque (vulnerable plaque). 
Unstable plaque is characterized by a thin fibrous cap (thin cap fibroatheroma—TCFA) cov-
ering the big necrotic core around which revolves the inflammatory process and positive 
remodeling of the artery [9, 32, 33, 35]. A similar transformation in the atherosclerotic plaque 
has also been observed in the ICA. This location is responsible for TIA and strokes [9]. Positive 
remodeling of the artery proves that narrowing of its lumen does not have to be relevant, and 
it may not exceed 50–70% [9, 33]. The widespread use of statin drugs, especially atorvas-
tatin and rosuvastatin, also likely ACE inhibitors, and lifestyle changes in developed coun-
tries have resulted in better control of inflammatory changes ongoing inside atherosclerotic 
plaque. This results in reduction in the incidence of strokes (primary stroke prevention) and 
ACS in the form of STEMI, but higher prevalence of NSTEMI and UA [9, 13, 32]. As a result, 
this has led to decreased cardiovascular mortality in many countries. It cannot be excluded 
that control of inflammation in the vessel wall by commonly used statins lowers the incidence 
of share in causes for destabilizing plaque rupture leading to occlusion of the artery. Because 
the total number of ACS and cerebral ischemic events remains at a similar level, this finding 
probably reveals other mechanisms leading to intravascular thrombosis with a smaller share 
of acute inflammation within the plaque rupture-induced accumulation of oxygen-modified 
LDL cholesterol (oxy-LDL) leading to destabilization. These mechanisms include endothelial 
injury by vascular flow disorders caused by artery stenosis, abnormal healing processes of 
the damaged endothelium, infectious pathogens as well as autoimmune responses against 
modified plaque components [9, 13, 35, 38, 39].
4. The evolution of stable coronary artery disease to ACS
4.1. Vulnerable plaque
Endocrine endothelial function, which consists in the synthesis and secretion of NO and 
PGI, is a prerequisite for the preservation of its integrity and correct relationship between 
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it and flowing blood. Known atherosclerotic risk factors may interfere with this function of 
encouraging the penetration of lipoproteins, monocytes and lymphocytes into the vessel wall. 
Currently, there is no doubt that atherosclerosis is a chronic inflammatory disease involving 
many immunological processes. Some researchers of these medical conditions compare them 
with other chronic inflammatory disorders, in which immune and autoimmune reactions 
play an important role [40, 41].
Inflammation in connexion with the accumulation of cholesterol, principally oxygen-modified 
LDL cholesterol (oxy-LDL), causes the proliferation of monocytes from peripheral blood, 
which is then converted into macrophages. It also stimulates the recruitment of myofibroblasts 
producing proteoglycans—the main substrate of extracellular matrix. Changes are condu-
cive to the occurrence of the vasoconstriction and activation of the endovascular inflam-
matory and prothrombotic mechanisms. Gradual increase of the volume of the emerging 
plaque leads to abnormal blood flow, which in turn causes the oscillating shear stress and 
intensifies the atherothrombotic mechanisms stimulating further plaque growth [35, 42, 43]. 
The resultant atherosclerotic plaque is made of fibrous cap of smooth muscle cells and con-
nective tissue. The cap separates the lumen of vessels from the contents in which necrotic 
core is surrounded by inflammatory infiltrates containing macrophages, foam cells and 
lymphocytes. The core of the plaque also contains the oxy-LDL cholesterol, free cholesterol 
crystals and calcium deposits [13, 43–46]. A part of the atherosclerotic plaques also contains 
foci of hemorrhage arising from the damage to the proliferating blood vessels, stimulated 
by inflammation [37, 47, 48]. Angiogenesis plays an important role in the pathophysiology 
of plaque instability and plaque rupture. New blood vessels rarely penetrate from the main 
lumen, but more often from the vasa vasorum [47, 48]. They lack the cells constituting the 
vessel wall which are fragile and porous, so that they become a source of local extravasation 
plasma protein and blood cells. Such bleedings in the plaque are frequent, may increase 
the volume of necrotic core and cause sudden progression of artery stenosis [49]. A central 
role both in the development and destabilization of plaque was attributed to macrophages, 
which, through their surface scavenger receptors, absorb oxy-LDL and transform into foam 
cells. Cytokines produced by macrophages infiltrates would lead to the degradation of the 
connective matrix tissue and smooth muscle cell necrosis and, consequently, to fibrous cap 
rupture. It leads to a thrombus formation responsible for acute ischemic syndromes. It has 
been repeatedly described for years as a mechanism of emergence and rise of the plaque 
volume, as well as its destabilization, is simplistic and does not actually translate the com-
plex changes taking place in its interior.
Currently, a greater role in initiation of changes is attributed to lymphocytes and mutual 
relations between lymphocytes and macrophages, which cause varying degrees of inflamma-
tion activity. The main antigen that initiates and maintains inflammation in the vessel wall 
is oxy-LDL [13, 32, 41, 50]. It is toxic to the vessel wall cells causing the immune system to 
try eliminating it. The presence of oxy-LDL-derived antigens on the surface of the dendritic 
cells, macrophages and different types of lymphocytes regulates the activity of inflammation 
[13, 41, 50, 51]. Antigen can also be protein of bacterial cells, viral, heat shock protein 60 or 
β2glycoprotein 1 [3].
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Naïve T-cells maturating in the thymus gland under the influence of natural antigens dif-
ferentiate into the cells of total immune memory, slow reacting (central memory—T
CM
) long 
remaining in circulation and storing the memory of antigens (e.g. cancer, HIV) and effec-
tor cells (effector memory—T
EM
) rapidly responsive and likely to produce cytokines [52]. 
The T
CM
 have the molecule CD27 on their surface. After contact with nominal antigens, they 
irreversibly lose surface molecule and can settle in the lymph nodes where they acquire 
the characteristics of T
EM
 [52]. These cells differentiate into the lymph nodes in the direc-
tion of various cell lines—helper (Th) and regulatory (Treg) [53]. Antigen-presenting cells 
(APC) play key role in direction of differentiation of T cells by stimulating their surface 
receptor (T-cell receptor—TCR). Under their influence, functionally differentiated Th cells 
arise, which are classified according to the type of produced cytokines, surface markers and 
expression of lineage specifying transcription factors. The direction of the differentiation of 
T cells depends on the antigen quantity and intensity of TCR stimulation and on cytokine-
inducing specific types of cells [39, 53]. It has been shown that circulating T lymphocytes, 
CD4+ and CD8+, differentiate preferentially in the direction of Th
1
, Th2 and Th17, which pro-motes the transformation from stable atherosclerotic plaque into unstable vulnerable plaque 
[9, 50, 51, 54]. Arising Th cells produce different cytokines, including interleukin 2 (IL-2), 
which controls immune processes by influencing the maturation of lymphocytes Treg dem-
onstrating immunosuppressive reactivity [13, 42, 50, 51, 53, 54]. It is now suspected that 
cell response (Th
1
, Th
17
) and its mediators: tumor necrosis factor-α (TNFα), interferon-γ 
(INFγ) and interleukins (IL)—IL-1β, IL-12, IL-17, IL-18 are responsible for promoting the 
development of atherosclerosis, whereas humoral immune response (Th2) and its mediators: IL-2 IL-4, IL-5, IL-10, IL-13 have an inhibitory effect on this process [3]. Propagators of the 
ongoing inflammation are increased levels of proinflammatory cytokines (i.e. TNF-α, IL-6); 
soluble adhesion-intercellular adhesion molecule (ICAM), vascular cell adhesion molecule 
(VCAM), l-selectin and so-called acute-phase proteins—inflammation C-reactive protein 
(CRP), amyloid A and fibrinogen [2].
The mechanism of lymphocytes penetration into the arterial wall is not exactly known. 
Probably this is done with the participation of chemokines and l-selectin [50]. Because most 
chemokine receptors are found on different cell types, research to clarify the mechanisms of 
lymphocytes homing in the atherosclerotic plaque is mostly inconclusive.
Th
1
 and Th
17
 cells produce large amounts of IFNγ that activates inflammatory processes and 
expresses the transcription factor β (T-bet). These factors play a decisive role in the destabi-
lization of atherosclerotic plaque. IFNγ activates APCs and macrophages, reduces collagen 
synthesis and increases production of cytokines degrading extracellular matrix. An important 
role in the degradation of the extracellular matrix is also played by matrix metalloproteinases 
(MMP) [9, 55, 56]. A strong factor in boosting the activity of MMP-9 (an enzyme that breaks 
down collagen type IV, which is component of the fibrous cap) is TNFα (Figure 1) [57].
Treg cells inhibit the inflammatory reactions by IL production such as IL-10 and similarly act-
ing transforming growth factor beta (TGFβ) [9, 13, 39, 50, 60]. They reinforce simultaneously 
the fibrous cap by stimulating the proliferation of smooth muscle cells and the production 
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Figure 1. Possible mechanisms of plaque vulnerability (left) and plaque endothelial erosion (right). Vulnerability: oxy-
modified LDL (oxy-LDL) causes inflammation by the proliferation of monocytes from peripheral blood, which is then 
converted into macrophages (M). The excess oxy-LDL in the blood penetrating into plaque results in the formation of the 
complexes with immunoglobulin (Ig). These complexes combine with Fc receptors (FcR) on the surface of macrophages 
stimulate the secretory activity for MMP, IL-1β and TNFα. Presentation of the oxy-LDL on the surface of macrophages 
stimulates Treg lymphocytes, which slows the inflammation by reducing the activity of the Th lymphocytes. Cell response 
(Th
1,
Th
17
) and its mediators—tumor necrosis factor-α (TNFα), interferon-γ (INFγ) and interleukins (IL-1β)—are responsible 
for promoting the development of atherosclerosis and activating inflammatory processes. IFNγ activates macrophages, 
reduces collagen synthesis and increases production of cytokines degrading extracellular matrix. Treg cells inhibit the 
inflammatory reactions by IL production (IL-10) and similarly acting transforming growth factor beta (TGFβ). The binding 
of oxy-LDL to scavenger receptor (ScR) located on macrophages, which is not subject to feedback, results in overloading 
of these cells leading to their death, releasing the free cholesterol and increasing volume of necrotic core. Such antigens, 
when released, trigger mechanisms of the vicious circle by stimulation of the Th
1
 and Th
17
 instead of Treg lymphocytes. 
Endothelial erosion: both low (LSS) and improperly high shear stress (HSS) interfere with endothelial functions and can 
produce prothrombotic state. Shear stress fluctuations increase tendency of endothelial cells covering the atherosclerotic 
plaque to apoptosis. Damage to the endothelial cells activates endothelial progenitor stem cells (EPCs) derived from bone 
marrow, which proliferate at the place of damage, and may prevent the described processes that leading to the thrombus 
formation. Endothelial cells increase their adhesion properties in relation to the platelets which by releasing granulation 
substances (IL-1β) activate the endothelial cells creating a mutual feedback. Reactive oxygen species (ROS) and circulating 
lipoprotein (oxy-LDL) also express endothelial surface adhesion proteins as selectins (P-sel) and von Willebrand factor 
(VWF), which supports the mutual relationships between them and platelets. Platelet CD40 ligand (CD40L) binds CD40 
on endothelial cells, resulting in upregulation of adhesive molecules (ICAM-1, VCAM-1, P-sel), cytokines, and TF release, 
leading to reduction in NO synthesis. Surface platelets glycoprotein-1 receptors for P-selectin (PSGL-1) allow for adhesive 
bond and rolling platelets but not strict binding to the endothelium. Glycoprotein surface receptor GPVI and αvβ3 bind 
vascular walls collagen causing the activation of receptors αIIbβ3 and release of ADP and thromboxane A2 (TxA2). The 
combination of glycoprotein platelet receptors αIIbβ3 with VWF and fibrinogen stabilizes the platelet clot. This initiates a 
platelet thrombus protruding into artery lumen and is essential for the later stages of thrombus formation.
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of collagen [39]. Functional balance between these T-cell types provides the stability of ath-
erosclerotic plaque. The excess oxy-LDL in the blood penetrating into plaque results in the 
formation of the complexes with immunoglobulin. These complexes combine with Fc recep-
tors (FcR) on the surface of macrophages and stimulate the secretory activity for MMP, IL-1β 
and TNFα. At the same time, the presentation of the oxy-LDL on the surface of macrophages 
stimulates Treg lymphocytes, which slow the inflammation down by reducing the activity of 
the Th lymphocytes. Such control system works well in people with low levels of risk factors. 
The binding of oxy-LDL to scavenger receptor located on macrophages, which is not subject 
to mentioned feedback, results in overloading of these cells leading to their death, releasing 
of free cholesterol and increasing volume of necrotic core [13, 58]. The release of such antigens 
triggers the mechanisms of the vicious circle by stimulation of the Th
1
 and Th
17
 instead of Treg 
lymphocytes [9, 13, 39, 42, 50].
Lately, attention is focused on the role of receptor programmed target death protein-1 (PD-1) 
presented on the naive CD8+ cells. It bears the responsibility for the so-called immune exhaus-
tion observed in chronic inflammatory states (tbc, HIV) and cancer. There are suggestions that 
chronic stimulation of TCR by oxy-LDL leads to increased presentation of PD-1. The presence of 
PD-1 correlates inversely with the level of IL-2 produced by Th2. This can interfere with the CD8+ cell differentiation in the direction of Treg and potentiate their apoptosis leading to competitive 
advantage mechanisms acting as pro-inflammatory and destabilizing factors in the plaque [41].
Probably within a plaque, there are three subtypes of macrophages. The most common are 
classically activated macrophages M1 induced by INFγ or Th
1
 and Th
17
 lymphocytes cyto-
kines. The second group are macrophages M2 induced by cytokines of helper lymphocytes Th2 (IL-4 and IL-13). They produce the anti-inflammatory acting cytokines—IL-10 and TGFβ [59]. 
Probably, there is a third group of macrophages presenting CD163+, activated by hemoglobin, 
which do not produce pro-inflammatory cytokines and have reduced ability to produce induc-
ible nitric oxide synthase (iNOS). A decrease in the levels of intracellular iron ions within the 
macrophage probably plays a leading role in the transcription of genes protecting these secu-
rity cells from the accumulation of lipids. This is done by increase in the levels of ferroportin-1 
leading to reduction of free radicals (-OH) production as result of iron ions accumulation and 
depletion. One of the key regulators of atherosclerotic plaque stability may prove to be hepci-
din, responsible for ferroprotein-1 degradation, resulting in the accumulation of iron ions, the 
accumulation of intracellular lipids and apoptosis of macrophages. Hepcidin blockage inhibits 
the development of atherosclerosis by regulating ATP-binding protein subfamily G [59, 60].
A significant role in the weakening of the fibrous cap, consequently causing it to rupture, 
is played by T-cells CD4 + CD28nul. They produce a significant amount of INFγ and TNFα, 
strongly stimulating macrophages. They also have cytotoxic properties in relation to fibrous 
cap, smooth muscle cells and are apoptosis resistant. These cells are presenting cytotoxic 
immunoglobulin (killer immunoglobulin) on their cell membrane that acts as cytotoxic recep-
tors (Ig-like receptors).
They also produce cytolytic enzymes against the endothelial cells that directly kill them, such 
as perforins, granzyme A and granzyme B, which are usually present in killer T cells (KTC) 
and natural killer cells (NK) [13, 39, 61, 62]. It has been shown that the number of these cells in 
the circulation is an important prognostic for occurrence and course of ACS [61].
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Production of proinflammatory proteins, such as IL-1β, chemokine (C-C motif) ligand 2 
(CCL2), chemokine (C-C motif) ligand 3 (CCL3), E-selectin (SELE), ICAM-1, MMP-3 and the 
MMP-9, involved in the process of destabilizing atherosclerotic plaque denotes a genetic pro-
file connected with polymorphism of many genes. Polymorphism of this plays an important 
role in the susceptibility to risk factors for atherosclerosis and to changes in already exist-
ing atherosclerotic plaque. What’s more, single nucleotide polymorphisms located within the 
regions of functional genes for these proteins may affect their concentration and activity caus-
ing further clinical implications [63].
By examining the mechanisms leading to the development of atherosclerosis, it was shown 
that in these processes, beyond the stimulated endothelial cell and cells of the immune sys-
tem, also vascular smooth muscle cells (VSMC) are involved [64]. VSMC function is not just 
limited to the production of extracellular matrix in the vessel wall. It has been shown that in 
response to a stimulus, these cells may change the type of produced extracellular matrix and 
thus affect the lipid content in the vessel wall and the multiplication of other cells. Under spe-
cific conditions, they can also take over the function of other cells, for example macrophages, 
and due to the expression of the relevant receptors acquire absorption capacity of fat by mim-
icking foam cells. While taking over some functions of endothelial cells, they can produce cell 
adhesion molecules, VCAM-1 or ICAM-1. In addition, being a component of atherosclerotic 
plaque, they can also produce cytokines—platelet-derived growth factor (PDGF), TGFβ, IFN 
and monocyte chemoattractant protein 1 (MCP-1) [64].
Under the influence of these cytokine, extracellular matrix degradation occurs into fibrous 
cap. It is weakened further due to result of the apoptosis of smooth muscle cells and cell death 
due to primary necrosis (oncosis) [9, 44].
Contact of the flowing blood with the content of the ruptured plaque activates processes of 
coagulation, which can occur rapidly. A large amount of tissue factor (TF) liberated by inflam-
mation tissue activates plasma factor VII, which runs the enzymatic coagulation cascade. TF 
forms a complex with factor VII, activating it to active form (VIIa). The complexes TF/VIIa 
activate factors IX and X, leading to thrombin generation. The consequence of this cascade of 
activation is rapid formation of the intravascular thrombus [9, 35, 65].
4.2. Erosion on the surface of the atherosclerotic plaque as a cause of ACS and 
stroke
Epidemiological studies have shown that myocardial infarction may occur in people with 
normal levels of LDL cholesterol. In addition, as demonstrated by pathomorphological 
and clinical studies using optical coherence tomography, 30-40% of patients with vascular 
thrombosis atherosclerotic plague have no inflammatory features [13, 45, 46]. The mor-
phology of such plaques is completely different from the above, subjected to the inflamma-
tory changes. The blood clot formed on its surface is in direct contact with the intima at a 
place completely devoid of the endothelium. Fibrous cap is well demarcated and includes 
numerous smooth muscle cells and an extensive connective tissue forming an extracellular 
matrix [33, 46]. The interior of the well-demarcated plaque contains few macrophages and 
 lymphocytes. As well, the profile of patients with ACS, who have been found to have this 
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type of plaque, differed from the profile of patients who suffered vulnerable plaque. In 
available reports, these patients were younger, 80% of these were premenopausal women, 
and frequent tobacco smokers [9, 33, 45]. The mass of the plaque, which was the basis of 
thrombosis, was less than in the case of plaque rupture and often it was nonconcentric 
[9, 13, 33, 45]. In contrast to the inflammatory plaques that show positive remodeling, 
arteries affected by erosion are characterized by negative one [45]. Demonstrated charac-
teristics suggest a different mechanism in formation of a blood thrombus, which, like in 
the case of plaque rupture, can cause both the closure of an artery and peripheral embo-
lism, more often associated with such morphology of the intravascular changes [9, 13, 
33, 45]. However, the mechanism of the formation of this type of inter arterial throm-
bosis has not been fully understood. It is suspected that a decisive role in its formation 
plays abnormal blood flow due to arterial plaque stenosis, which causes changes in shear 
stress, endothelial dysfunction that covers plaque affecting its anti-inflammatory and anti-
thrombotic signals of the endothelium [9, 13]. Laminar flow disorders more often occur 
in places of bifurcation and in the folds of the arteries. The correct endocrine function of 
the endothelium creates normal shear stress, which is the force of friction between the 
flowing blood and cellular layer covering the interior surface of the vessel. Both low and 
improperly high shear stress interfere with endothelial functions and can produce pro-
thrombotic state. In the case of atherosclerotic narrowing of the artery, both pre- and post-
stenosis flow are slowed down—shear stress is low, whereas at the apex of the plaque, the 
flow is accelerated—shear stress is abnormally high. This creates conditions conducive to 
damaged endothelium. Low shear stress and turbulent blood flow facilitate the accumu-
lation of lipids, the recruitment of inflammatory cells and increased expression of adhe-
sion molecules and proteases [59]. The correct vascular flow—valid shear stress induces 
the enzyme systems that prevent the expression of pro-inflammatory and pro-thrombotic 
genes and at the same time promote the layout security by activating the endothelial NO 
synthase. Simultaneously, high shear stress stimulates the synthesis of several types of 
microRNAs that interact with Krüppel-like factor 2 (KLF2) and nuclear factor erythroid 
cell-specific 2-related factor2 (Nrf2), which support the interaction of anti-inflammatory 
and anti-thrombotic pathways [13]. Accelerated flow of blood within the largest narrow-
ing and supra-physiologically high shear stress suppresses these systems, which prevent 
inflammation and activate the prothrombotic processes, and may be the reason for damage 
to the endothelial cells and the activation of inflammation with further consequences of 
thrombosis [9, 13]. These biomechanical force fluctuations associated with shear stress are 
particularly apparent in people with hypertension and their effects are intensified under 
the influence of other atherosclerotic risk factors, such as hypercholesterolemia, advanced 
glycation end-products in diabetes, tobacco smoking, vasoactive amines and immune 
complexes. These factors in terms of alternating shear stress can lead to endothelial dys-
function [35].
In areas of damaged vascular endothelium and high shear stress, there are abnormal inter-
actions between thrombocytes and endothelial cells, which is the basis for the pathogen-
esis of endovascular thrombosis and activates the processes leading to instability of the 
 atherosclerotic plaque. Another suggested mechanism that can coexist with described above 
is increased tendency of endothelial cells covering the atherosclerotic plaque to apoptosis. It is 
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associated with the possibility of presentation by so-called pattern recognition receptor—toll-
like receptor 2 (TLR2). It contains a hyaluronian molecules in its structure, identical to that 
found in Gram+ bacteria, which can result in the recognition of these cells as foreign by the 
immune system, leading to their destruction, and thus initiating thrombotic processes. This 
may lead to identification of these cells by the immune system as foreign, leading to damage 
and thus initiating the processes of thrombosis [9].
In the event of existence of some pro-inflammatory agents, endothelial cells increase their 
adhesion properties in relation to the platelets which by releasing granulation substances 
activate the endothelial cells creating a mutual feedback. Platelets associated with endothe-
lial cells become very effective in recruiting leukocytes in blood by promoting their adhe-
sion and transmigration within the atherosclerotic plaque. They play such an important 
role due to the interaction of numerous cell types such as endothelial cells, neutrophils, 
monocytes, dendritic cells and cytotoxic T-cells. Under physiological conditions, platelets 
circulate in the blood remaining in close contact with the endothelial cells. However, their 
adhesion is prevented by a specific phenotype of endothelium cells controlled by three 
intracellular ways: way of NO, trace ectoADPase/CD39/NTPDase and eicosanoids-arachi-
donic acid-prostacyclin pathway (PGI2), which inhibit the activation of platelets on the way 
of synthesis of cAMP and cGMP stimulation [59]. Impairment of these three mechanisms 
causes the expression of cell adhesion particles and then a multistep process coagulation 
cascade activation involving bondage, translocation and strict adhesion of platelets to the 
inner layer of the vessel [65]. Activated blood plate increases its volume, which denotes car-
diovascular risk, and is used in the clinical trial identification of inflammation and accom-
panying prothrombotic state [66, 67].
Activation of endothelial cells, arising not only under the influence of flow disorders but 
also under the influence of reactive oxygen species (ROS), and circulating lipoprotein leads 
to the expression of surface adhesion proteins—P-i l-selectin and von Willebrand factor 
(VWF), which support the mutual relationships between endothelial cells and platelets [65]. 
Endothelial cells present selectin on their surface, such as selectin-P, which stimulate plate-
lets to produce glycoproteins, including glycoprotein-1. Complex selectin-P-glycoprotein-1 
(PSGL-1) allows platelet adhesion and rolling but not tight binding of endothelial cells. 
Glycoprotein surface receptors GPVI and αvβ3 bind vascular walls collagen, which activates 
the channels for intracellular calcium flux, causing the activation of receptors αIIbβ3 and 
release of ADP and thromboxane A2 (TxA2). This initiates a platelet thrombus protruding 
into artery lumen and is essential for the later stages of thrombus formation. The combination 
of glycoprotein platelet receptors αIIbβ3 with VWF and fibrinogen stabilizes the platelet clot, 
which in clinical practice becomes the target of preventing thrombolysis by pharmacological 
interventions (Figure 1) [65]. Impregnation of so-formed platelets conglomerate on the inner 
surface of the artery by fibrin finally decides the formation of a stable thrombus [9, 65].
Mutual activation of endothelium and platelets largely depends on the IL-1β, accumu-
lated in granules of platelets and activated by mRNA already several hours after thrombin 
stimulation or adhesion-dependent integrins. Stimulation of platelets by IL-1β induces 
secretion of IL-6 and IL-8 and the expression of surface adhesion molecules-ICAM-1, αvβ3 
and hemotactic monocyte’s protein-1 (MCP-1). Due to these mechanisms, platelets are 
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capable of recruiting monocytes and neutrophils from blood and then causing them to 
migrate and participate in the above described pathophysiology of atherosclerotic plaque 
vulnerability. Presented mechanisms ensure the presence of activated thrombocytes in the 
center of the pathophysiology of the process, not only with the thrombus formation but 
also as an important part in the activation and maintenance of the inflammatory process. 
Human platelets are capable of producing all types of toll-like receptors (TLR). It has 
been shown that higher TLR expression in women may be responsible for differences in 
cardiovascular risk profile, as well as the tendency for a higher incidence of ACS in the 
superficial thrombosis mechanism, without active inflammatory features in the athero-
sclerotic plaque [9, 59, 65].
Damage to the endothelial cells activates endothelial progenitor stem cells (EPCs) derived 
from bone marrow, which proliferate at the place of damage and may prevent the described 
processes that leading to the thrombus formation. These repair mechanisms are defective in 
patients with diabetes, characterized by a general weakness of repair capacity of damaged 
tissues [13, 33].
4.3. Artery calcification
Calcification in the arteries is especially visible in the carotid arteries. The relationship of cal-
cification with instability of atherosclerotic plaques was not proven and is rather dubious [33]. 
It is suspected that calcifications are the result of increased apoptosis of smooth muscle cells 
and bleeding inside the atherosclerotic plaque [33].
Previously, it was thought that the calcification in the arterial walls increases the risk of car-
diovascular complications [68]. Research in recent years has not shown; however, that calcifi-
cations increase the risk of plaque destabilization, and even reversely, calcified atherosclerotic 
plaques are now considered to be more stable [66, 67, 69, 70].
It has been shown that in the process of vascular calcification same changes occur as in the 
process of mineralization of bone tissue [33, 68]. Calcification of arteries in atherosclerosis is 
an active process and a complicated arrangement of mediators and calcification inhibitors is 
involved in it. This process includes participation of many cells (monocytes/macrophages, 
smooth muscle cells, vascular endothelial cells) and a variety of substances and transcription 
factors that are specific to bone rebuilding [71].
Emphasis is placed on separate pathomechanism of calcification of the arteries in patients 
with DM2 as compared with non-diabetic patients [2]. It has been proved that serum pro-
teins like glycosylated albumin, through nuclear factor kappa-lightchain-enhancer of acti-
vated B cells (NFkB), mitogen-activated protein kinase (MAPK) and p38 kinase MAPK, leads 
to activation of vascular smooth muscle cells, which leads to the induction of inflammatory 
response, proliferation and migration of cells [72].
The dependence of calcifications on age and their predominance in men gender  is under-
lined. The current prevailing opinion is that the presence of calcification demonstrates the 
extent and progress of atherosclerosis and identifies the risk of the patient generally associ-
ated with atherosclerosis and not directly related to the acute cardiovascular risk [70].
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5. Summary
Progress within understanding the causes of the described disorders and the mechanisms 
leading to the formation of a blood clot opens up new therapeutic possibilities now and in 
the future to prevent acute cardiovascular incidents. The importance of the anti-inflammatory 
activity of statins as shown in many studies proving their clinical efficacy has already been 
mentioned. Similar importance has been demonstrated for other forms of therapy to lower 
LDL cholesterol with the help of ezetimibe or evolocumab. Controlling inflammation with 
patient behavior and statin drugs administration reveals other mechanisms leading to desta-
bilization of atherosclerotic plaques. It cannot be ruled out that statins act on different levels 
of ongoing inflammation. In patients with HIV, there exist demonstrated beneficial effects of 
rosuvastatin, which reduced the presentation of PD-1 receptor on the surface of naïve-CD8+ 
[41]. It cannot be ruled out that it may be an indirect effect of its activity, by lowering levels of
LDL cholesterol. Similar effects, including other pathways, leading to increased production of 
IL-2 and the intensification of differentiate naïve-CD8+ lymphocytes in the direction of Treg 
can restore the immunological balance and prevent destabilization of inflammatory athero-
sclerotic plaque [41].
Understanding of the immunological mechanisms, vulnerability of atherosclerotic plaque 
creates the chance to obtain antibodies against antigens involved in this process. The mul-
titude of these antigens operating at different stages of development is currently an impor-
tant difficulty. There exist attempts to gain effective antibodies against oxy-LDL, the key 
antigen for activation of inflammation and atherosclerosis. Research is directed into the 
efficacy and safety of antibodies directed against interleukins active in generating plaque 
instability. Some hopes are in the direction of tocilizumab, that is, IL-6 antagonist. The 
disadvantage to the trials that use anti-inflammatory medications is due to accompany-
ing increase in metabolic disorders of the lipid fraction which can negatively affect the 
progression of atherosclerotic lesion [34]. In the last published results of CANTOS study, 
it has been shown to reduce the risk of several percent in recurrent cardiovascular events 
after the monoclonal antibody—canakinumab application, which is the antagonist of 
IL-1β, and reduce the level of highly sensitive C-reactive protein without affecting the level 
of cholesterol. The result of this study was considered inflammatory confirmation theory 
of atherosclerosis and a new perspective in its treatment [73, 74]. An interesting sugges-
tion for therapy is in trying to influence the MMP family. Some of them, like MMPs-8; 
10; 12; 13, are the enzymes responsible for the destruction of the fibrous cap as well as 
plaque rupture, its stabilization and reconstruction. MMPs are an interesting target for 
therapy of acute coronary syndromes; however, their general inhibition may lead to oppo-
site effects [75].
Strong anti-inflammatory and anti-atherogenic effects have apoA-I, which is a protein com-
ponent of high-density lipoprotein HDL. HDL is responsible for the reverse transport of cho-
lesterol contained in the atherosclerotic plaque into the bloodstream. Change in aspect ratio 
of apoB/apoA-I can change the course of the atherosclerotic process. Significant in this regard 
are clinical studies [35].
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The chances of stabilizing atherosclerotic plaques also connect with the future possibility of 
affecting the subpopulations of T lymphocytes. Controlling activity of Th by increasing the 
impact of immunosuppressive Treg may foster chronicity process atherosclerosis and avoid 
exacerbations associated with inflammation [34].
Another investigation directed towards controlling the course of the disease is the effect on 
macrophages. Control of their pro-inflammatory function could prevent destabilization of 
atherosclerotic plaque by reducing their in-plaque activity [34].
Recognizing the importance of external antigens (bacterial and viral infections) in activating 
inflammatory process, it is proposed to use vaccination as a prevention of exacerbations [13, 34].
Ongoing attempts to intensify healing processes within using pluripotent stem cells and acti-
vate endothelial progenitor cells derived from bone marrow. Getting progress in this regard 
would be an opportunity to control endothelial dysfunction in the early stages of atheroscle-
rosis, particularly in patients with diabetes mellitus [13].
Above mentioned studies, as well as other ongoing multidirectionally experimental and clini-
cal studies, offer hope that in the future one will be able to better understand and control the 
processes leading to the initiation and progression of atherosclerosis and mechanisms of acti-
vation and worsening inflammatory changes that lead to intravascular thrombosis—direct 
causes of acute cardiovascular syndromes.
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